Objective. Type I interferon (IFN) signaling is a central pathogenic pathway in systemic lupus erythematosus (SLE), and therapeutics targeting type I IFN signaling are in development. Multiple proteins with overlapping functions play a role in IFN signaling, but the signaling events downstream of receptor engagement are unclear. This study was undertaken to investigate the roles of the type I and type II IFN signaling components IFN-a/b/v receptor 2 (IFNAR-2), IFN regulatory factor 9 (IRF-9), and STAT-1 in a mouse model of SLE.
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Objective. Type I interferon (IFN) signaling is a central pathogenic pathway in systemic lupus erythematosus (SLE), and therapeutics targeting type I IFN signaling are in development. Multiple proteins with overlapping functions play a role in IFN signaling, but the signaling events downstream of receptor engagement are unclear. This study was undertaken to investigate the roles of the type I and type II IFN signaling components IFN-a/b/v receptor 2 (IFNAR-2), IFN regulatory factor 9 (IRF-9), and STAT-1 in a mouse model of SLE.
Methods. We used immunohistochemical staining and highly multiplexed assays to characterize pathologic changes in histology, autoantibody production, cytokine/ chemokine profiles, and STAT phosphorylation in order to investigate the individual roles of IFNAR-2, IRF-9, and STAT-1 in MRL/lpr mice.
Results. We found that STAT-1 2/2 mice, but not IRF-9
2/2 or IFNAR-2 2/2 mice, developed interstitial nephritis characterized by infiltration with retinoic acid receptor-related orphan nuclear receptor gt-positive lymphocytes, macrophages, and eosinophils. Despite pronounced interstitial kidney disease and abnormal kidney function, STAT-1 2/2 mice had decreased proteinuria, glomerulonephritis, and autoantibody production. Phosphospecific flow cytometry revealed shunting of STAT phosphorylation from STAT-1 to STAT-3/4.
Conclusion. We describe unique contributions of STAT-1 to pathology in different kidney compartments in a mouse model, and provide potentially novel insight into tubulointerstitial nephritis, a poorly understood complication that predicts end-stage kidney disease in SLE patients.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by inflammatory destruction of multiple organs. Patients are treated with glucocorticoids, nonsteroidal antiinflammatory drugs, cytotoxic agents, hydroxychloroquine, mycophenolate mofetil, and rituximab, alone or in combination (1) . In the last decade, pathophysiologic pathways in SLE have been discovered and targeted. These include therapies targeting interferon-a (IFNa), a type I IFN (2) .
Evidence that IFNa plays a crucial role in SLE is extensive. A subset of patients who receive IFNa for hepatitis develop an SLE-like illness, ranging from development of antinuclear antibodies to frank autoimmunity that meets the diagnostic criteria for SLE (3) . Transcript profiling of bulk peripheral blood mononuclear cells and immune cell subsets from SLE patients demonstrated the presence of an IFNa-inducible gene expression signature or "IFN biosignature" (4) . This biosignature has been shown to correlate with the SLE Disease Activity Index (SLEDAI) (5) and the 1997 update of the American College of Rheumatology revised criteria for SLE (6, 7) .
The IFN biosignature has been robustly recapitulated in murine models of SLE (8) . However, results from groups studying lupus-prone mice lacking the a-chain of IFN-a/b receptor (IFN-a/bR; called IFNAR-1) are inconsistent, reporting either improved or worsened disease (9) (10) (11) . Our group has defined roles for IFN-a/b/ v receptor 2 (IFNAR-2), IFN regulatory factor 9 (IRF-9), and STAT-1 in mice with pristane-induced arthritis (12, 13) (details are available from the corresponding author upon request). We identified defects in Toll-like receptor 7 (TLR-7)-and TLR-9-specific B cell responses and isotype-switched IgG autoantibodies in IFNAR-2
2/2 , and STAT-1 2/2 mice. Because the pristane-induced model of arthritis is an inducible model associated with mild kidney pathology, the roles of IFNAR-2, IRF-9, and STAT-1 in the spontaneous development of organ-specific involvement, such as glomerulonephritis (GN), is unclear. In the MRL/lpr mouse model, SLE-like pathogenesis results from a lossof-function mutation in Fas (lymphoproliferation [lpr]), leading to defects in the negative selection of autoreactive B and T lymphocytes. MRL/lpr mice recapitulate human SLE pathologies, particularly the progressive immune complex-mediated GN seen in lupus nephritis, a leading cause of mortality (14) . Other features of the model include more frequent occurrence in females, diffuse organ inflammation, and autoantibodies against DNAand RNA-containing antigens (15) .
Given the plethora of cytokines dysregulated in autoimmunity promotion (16, 17) , there is growing interest in shared signaling pathways, including phosphorylation of STAT family members involved in IFN signaling. Binding of IFNAR by IFNa triggers phosphorylation of STAT-1/2 by JAK family proteins. This leads to formation of a heterotrimeric complex, IFN-stimulated transcription factor 3 (ISGF-3), composed of STAT-1, STAT-2, and IRF-9. Nuclear translocation of this complex enables binding to IFN-stimulated response element (ISRE). In contrast, IFNg binds to IFNgR and triggers phosphorylation of a STAT-1 homodimer, which binds g-activated site-containing genes. Downstream effects of both type I and type II signaling result in gene transcription, including those vital to immune function.
In this study, we investigated the individual contributions of the type I and type II IFN signaling components IFNAR-2, IRF-9, and STAT-1 to spontaneous SLE-like pathogenesis in the MRL/lpr mouse model. We hypothesized that ablation of any of the 3 IFN signaling components would result in an ameliorated disease phenotype. Instead, our findings support unique roles of IFNAR-2, IRF-9, and STAT-1 and demonstrate a critical role for STAT-1 in the development of Th17 cell-associated interstitial nephritis in SLE-like disease. This pathology mimics tubulointerstitial nephritis, which correlates with end-stage renal failure in SLE patients (18) . We further demonstrate marked Th17 enrichment in lymphoid organs, alterations in autoantibody profiles, and shunting of STAT-1 signaling to other cytokine pathways. Taken together, our results suggest that STAT-1 ablation leads to ameliorated glomerular disease in MRL/lpr mice, and to development of unanticipated effects on the immune system and interstitial nephritis.
MATERIALS AND METHODS
Mice. MRL/MpJ mice were purchased from The Jackson Laboratory. IFNAR-2 2/2 mice on the BALB/c background were kindly provided by Paul J. Hertzog (Monash University, Clayton, Victoria, Australia). IRF-9 2/2 mice on the BALB/c background were purchased from the RIKEN BioResource Center. STAT-1 2/2 mice on the BALB/c background were a generous gift from J. Durbin (Ohio State University, Columbus, OH). All knockout mice were backcrossed onto the MRL/lpr background (The Jackson Laboratory) to the N8-N10 generation. Data were obtained in female mice at 16 weeks of age. Every mouse analyzed in this study was genotyped for the presence or absence of the gene of interest (data available from the corresponding author upon request).
Histopathology and immunohistochemical staining. Mice were euthanized by CO 2 exposure followed by cervical dislocation. Kidneys were surgically removed, fixed in buffered formalin, embedded in paraffin, sectioned, and stained with either periodic acid-Schiff (PAS) or hematoxylin and eosin (H&E) or stained for CD45 (30-F11; BD PharMingen) (performed by Histo-Tec). The slides were scored in a blinded manner by one of the authors (JF) according to the National Institutes of Health (NIH) kidney scoring system (19) for both active and chronic disease (details are available from the corresponding author upon request).
Immunofluorescence staining. Mice were injected intraperitoneally with ketamine (100 mg/kg) and diazepam (5 mg/kg) and transcardially perfused with 30 ml of phosphate buffered saline (PBS)-EDTA followed by 30 ml of 4% paraformaldehyde (weight/volume) in 0.1M PBS at room temperature. Kidneys were removed and then fixed in 4% paraformaldehyde at 48C for up to 24 hours and then cryoprotected in 24% sucrose solution (w/v) in PBS for 24 hours. Kidneys were embedded in OCT compound (Tissue-Tek), frozen at 2808C, and then cut into 7-mm sections. Sections were thawed at 208C, rehydrated in PBS for 2 hours, and then treated with 0.3% Triton in PBS for 30 minutes. Three hundred microliters of cold acetone was added to each section for 15 minutes at 2208C and washed with PBS 3 times. Blocking was performed with 5-10 mg=ml anti-CD16/32 for 2 hours. Primary antibody staining was performed overnight at 48C for the following molecules: retinoic acid receptor-related orphan nuclear receptor gt (RORgt) (AFKJS-9; eBioscience), ionized calcium-binding adapter molecule 1 (IBA-1) (catalog no. 019-19741; Wako), and IgM (1020-01; SouthernBiotech). Secondary antibody staining was performed using donkey anti-goat Alexa Fluor 647, donkey anti-rabbit Alexa Fluor 568, or donkey anti-rat Alexa Fluor 488 (Molecular Probes) in the dark for 1 hour at room temperature. All sections were analyzed by confocal microscopy using either a Leica SP2 AOBS confocal microscope or a Leica SP8 confocal microscope. All images presented are maximum intensity projections of z stacks of individual optical sections.
Cytokine stimulation and phospho-flow cytometry. Splenocytes were cultured for at least 2 hours and stained for viability with Aqua Amine Live/Dead cell stain (Invitrogen) for 30 minutes. Following washing and resting for 30 minutes, splenocytes were stimulated with IFNa (1,000 units/ml; PBL InterferonSource), IFNg (50 ng/ml; PeproTech), interleukin-4 (IL-4) (50 ng/ml; PeproTech), IL-12 (50 ng/ml; PeproTech,), IL-21 (50 ng/ml; PeproTech), or IL-27 (50 ng/ml; R&D Systems) for 20 minutes at 378C. Stimulation was halted with 1.6% paraformaldehyde for 10 minutes at room temperature. Following washing with fluorescence-activated cell sorting (FACS) buffer (0.5% bovine serum albumin and 0.09% sodium azide in PBS), splenocytes were permeabilized using prechilled methanol for 20 minutes at 48C. Following washing, cells were stained for 1 hour at room temperature with fluorophore-conjugated surface antibodies (a list is available from the corresponding author upon request). Following washing, cells were fixed with 1.6% paraformaldehyde and analyzed by LSRII (Becton Dickinson).
Additional details regarding mice, intracellular cytokine staining, lupus autoantigen microarrays, enzyme-linked immunosorbent assays (ELISAs), real-time quantitative polymerase chain reaction (qPCR), Luminex multiple cytokine/ chemokine assay, and statistical methods are available from the corresponding author upon request.
RESULTS
Decreased proteinuria in mice deficient in type I or type II IFN and elevated renal function markers in STAT-1 2/2 mice. A hallmark of human and murine SLE is the development of GN, in which immune complex deposition in glomeruli results in inflammation and failure to retain proteins (20, 21) . We hypothesized that mice with defects in IFN signaling would have less severe inflammation and thus would be protected against GN development. We assessed proteinuria in female MRL/lpr mice lacking IFNAR-2 (IFNAR-2 mice, at 16 weeks to allow for disease development in organ systems including the kidneys (22) . MRL/MpJ mice lack the lpr mutation and were used as a control strain. As expected, MRL/lpr mice developed significantly higher levels of proteinuria than MRL/MpJ controls (P , 0.0001) (Figure 1a ). Mice lacking IFNAR-2, IRF-9, or STAT-1 all exhibited significantly decreased proteinuria compared to MRL/lpr mice (P 5 0.02, P , 0.0001, and P , 0.0001, respectively), indicating relatively preserved glomerular function, consistent with our initial hypothesis.
IFNAR-2 and IRF-9 ablation led to decreased serum levels of both creatinine and blood urea nitrogen (BUN) compared to MRL/lpr mice, although the differences were not statistically significant (Figures 1b and c). As expected, MRL/lpr mice had significantly higher serum levels of both creatinine and BUN than MRL/ MpJ mice (P 5 0.01). Surprisingly, STAT-1 2/2 mice also exhibited increased creatinine and BUN levels compared to MRL/MpJ mice, suggesting poor renal function despite improved proteinuria (P 5 0.01 for creatinine and P 5 0.03 for BUN). Unexpected development of interstitial kidney disease in STAT-1 2/2 mice. Kidney disease in SLE patients can be categorized into distinctive classes in which different areas of the kidney are affected. Because proteinuria is largely a measure of glomerular damage, further experiments were performed to assess global kidney morphology. We performed PAS staining on sections prepared from paraffin-embedded mouse kidneys (Figure 2a ) and quantified renal nephritis using the NIH activity and chronicity indices in a blinded manner (details are available from the corresponding author upon request).
As we predicted, IRF-9 2/2 and STAT-1 2/2 mice exhibited lower active and chronic glomerular scores than MRL/lpr mice, although the difference was not statistically significant (Figures 2b-e) . Conversely, IFNAR-2 2/2 mouse kidneys had increased active and chronic glomerular scores as compared to MRL/lpr mouse kidneys, although this difference also was not statistically significant. Unexpectedly, STAT-1 2/2 mouse kidneys showed significantly increased active and chronic tubulointerstitial pathology compared to MRL/ lpr mouse kidneys (P 5 0.0007 and P 5 0.0002, respectively) (Figures 2d and e) . To further investigate this finding, we performed immunohistochemical staining of kidney sections for the leukocyte marker CD45 ( Figure  2a) . We observed marked interstitial infiltration of CD451 leukocytes in kidneys from STAT-1 2/2 mice as compared to IFNAR-2 2/2 , IRF-9 2/2 , MRL/lpr, and MRL/MpJ mice, suggesting that an immune cell-mediated process was responsible for the tubulointerstitial disease.
Infiltration of the interstitium by RORgtpositive cells in STAT-1 2/2 mice. The GN observed in MRL/lpr mice is a B cell-associated process characterized by deposition of IgM/IgG (21) . Elevated levels of Th17 lymphocytes, a subset of inflammatory T cells, have also been observed in both the peripheral blood and kidneys of lupus nephritis patients (23) . To better characterize the immune cell infiltrate within the interstitium of knockout mice, we performed a series of immunohistochemical stainings for RORgt (the canonical transcription factor required for Th17 cell development), IBA-1 (a macrophage marker), and eosinophils. Both macrophages (24) and eosinophils (25) have been identified in the polarization and downstream function of Th17 lymphocytes.
As expected, MRL/lpr mouse kidneys showed increased IgM and IgG deposition in the glomeruli compared to kidneys from BALB/c mice (Figure 3a ). In contrast, minimal staining for IgM and IgG was observed in the glomeruli of STAT-1 2/2 mice, suggesting that other factors and/or cell types are involved. We observed notable infiltration of RORgt-positive cells confined to the interstitium of STAT-1 2/2 mice (Figure 3a) . The STAT-1 2/2 mouse interstitium also demonstrated increased H&E staining for IBA-1 (Figure 3a) and eosinophils (results are available from the corresponding author upon request). Taken together, the findings of histologic evaluation of kidney specimens indicate a role for RORgt-positive cells in mice lacking STAT-1, in contrast with the central role played by B lymphocytes in MRL/lpr mice with GN.
Altered Th1/Th17 polarization in mice deficient in type I and type II IFN signaling. In addition to their role in kidney disease, the circulating Th17 cell population is increased in SLE patients (26) . We hypothesized that ablation of STAT-1 would lead to increased Th17 polarization in secondary lymphoid organs. We quantified the proportions of IL-17A-and IFNg-producing lymphocytes in the mouse spleen and lymph nodes (axillary, mandibular, and mesenteric) by flow cytometry.
The proportion of IL-17A1CD41 T cells was increased in STAT-1 2/2 mouse splenocytes by .8 fold compared to MRL/lpr mouse splenocytes (0.84% versus 0.10%; P 5 0.0007) (Figures 3b and c) . No significant changes were observed in the frequencies of IL-17A-producing CD41 T cells in IFNAR-2 2/2 mice and IRF-9 2/2 mice (0.15% and 0.04%, respectively) as compared to MRL/lpr mice (Figures 3b and c) . To test whether the absence of STAT-1 alone would lead to expansion of the Th17 lymphocyte population, intracellular cytokine staining of IL-17A was also performed on BALB/c mouse splenocytes lacking STAT-1. No significant enrichment was found when compared to wild-type BALB/c mice (data are available from the corresponding author upon request).
As expected, fewer IFNg-producing CD41 T cells were observed in the spleen and lymph nodes obtained from STAT-1 2/2 mice than in cells obtained from MRL/ lpr mice (12.12% and 30.02%, respectively, in the spleen; P 5 0.004) (Figures 3b and d) . IFNAR-2 2/2 and IRF-9 2/2 mice had significantly larger populations of IFNgproducing CD41 T cells in the spleen (42.56% and 53.6%, respectively; P 5 0.0185) (Figures 3b and d) . These results suggest cross-talk between type I IFN and type II IFN signaling. In the absence of type I IFN signaling proteins, a compensatory increase in IFNg signaling is observed, likely mediated by STAT-1 shunting. Decreased production of IgM/IgG autoantibodies against SLE-associated antigens in STAT-1 2/2 mice. Antibodies directed against autoantigens are clinically relevant in GN (27) , while the role of autoantibodies in interstitial kidney disease is not well understood.
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We used protein microarrays to profile autoantibodies in the sera of our mice. This method has been well established by our laboratory for studying human SLE (28-30) and murine SLE (12, 13, 31) . Briefly, arrays containing .600 features and 100 unique proteins and peptides were printed and probed with sera, and bound autoantibodies were detected with a fluorophoreconjugated secondary antibody. Arrays were scanned, and fluorescence intensity was quantitated. The Significance Analysis of Microarrays (SAM) algorithm (32) was used to determine antigens with statistically significant differences between groups of mice, and a hierarchical clustering program was used to group individual mice based on similar autoantibody profiles. IgM autoantibody reactivity against SLEassociated autoantigens was decreased in STAT-1 2/2 mice compared to MRL/lpr mice (Figure 4a ). SAM identified 12 of these IgM autoantibodies as significantly decreased in STAT-1 2/2 mouse sera compared to MRL/ lpr mouse sera. Differentially targeted autoantigens included U1 small nuclear RNP, histones, and doublestranded DNA, all of which are important in human SLE. SAM identified a similar but constricted subset of IgG autoantibodies that were significantly decreased in STAT-1 2/2 compared to MRL/lpr mouse sera ( Figure  4b) .
When comparing IRF-9 2/2 and MRL/lpr mouse sera, SAM identified increased IgM and IgG autoantibody reactivity against histones in IRF-9 2/2 mouse sera (results are available from the corresponding author upon request). These data reveal a potentially unique role for IRF-9 in antibody production against histones. We did not identify any antigens with significantly different reactivity when comparing IFNAR-2 2/2 and MRL/lpr mouse sera. Of 22 significant array findings, 17 were validated as significant using ELISA (Figure 4c ) (data are available from the corresponding author upon request).
STAT-1 is required for the expression and upregulation of TLR-7 by IFNa. Nucleic acid components of SLE autoantigens can activate autoreactive B cells via TLRs. TLR expression is also up-regulated by type I IFN secreted by plasmacytoid dendritic cells in human naive B cells and modulates isotype switching (33) . We have previously demonstrated in the pristaneinduced model that mice lacking IFNAR-2, IRF-9, or STAT-1 have defects in up-regulating TLR-7 and/or TLR-9 expression in response to IFNa exposure (12, 13) . Moreover, STAT-1 2/2 mice with pristaneinduced arthritis had a marked defect in isotype switching of autoantigen-specific B cells, but not B cells immunized with ovalbumin. We hypothesized that the decreased autoantibody production observed in STAT-1 2/2 MRL/lpr mice was due to a similar defect in TLR-7/9 up-regulation.
Splenic B cells were obtained from STAT-1
and MRL/lpr mice and cultured in the presence or absence of IFNa, and relative expression levels of mRNA for TLR-7, TLR-9, and Mx1 (a known IFNainducible gene) were determined by real-time qPCR.
The expression of TLR-7, but not TLR-9, was significantly up-regulated in IFNa-treated B cells from MRL/ lpr mice, but this up-regulation was abolished in STAT-1 2/2 mouse B cells (Figure 4d) . We conclude that STAT-1 is required for IFNa-inducible expression of TLR-7, but not TLR-9, in murine B cells. Because STAT-1 2/2 mice have decreased reactivity against both DNA-and RNA-associated antigens, these data suggest overlap of RNA/DNA-sensing by TLR-7/TLR-9 (34). Alternatively, it is possible that defects in autoantibody production in STAT-1 2/2 mice result from TLRindependent pathways.
As expected, induction of expression of Mx-1 mRNA was significantly decreased in B cells from STAT-1 2/2 mice compared to MRL/lpr mouse B cells (P 5 0.016) (Figure 4e) . Notably, however, STAT-1 2/2 mouse B cells stimulated with IFNa retained the ability to significantly up-regulate Mx-1 expression as compared to unstimulated cells (P 5 0.02) (Figure 4e ), revealing that STAT-1 is dispensable for IFNa signaling. This finding supports work demonstrating high redundancy and plasticity of STAT phosphorylation in different physiologic states (35, 36) . We tested the hypothesis that IFNa signaling can signal through molecules other than STAT-1 using phospho-flow cytometry.
Shunting of STAT phosphorylation to different cytokine signaling pathways after disruption of genes encoding type I and type II IFN signaling proteins. Several groups have demonstrated that dysregulated STAT signaling plays a role in murine models of SLE and in human SLE patients (37) . We hypothesized that both Th1/Th17 polarization and transcription events downstream of IFNa signaling that are observed in the absence of type I and type II IFN signaling proteins could be attributed to dysregulated STAT signaling.
Splenocytes from individual mice were isolated and stimulated with individual cytokines for 20 minutes. We then used phospho-flow cytometry to measure the phosphorylation of STATs 1, 3, 4, 5, and 6 in CD41 T cells (CD31CD41CD82), CD81 T cells (CD31CD42 CD81), and B cells (CD32CD42CD191) from our mice. We selected cytokines thought to play critical roles in SLE pathogenesis, including IFNa, IFNg, IL-21, and IL-27 (4, 17) . To identify additional cytokines to include in the stimulation panel, we performed a multiplex beadbased assay on STAT-1
, and MRL/lpr mouse serum to determine levels of 26 different cytokines and chemokines (results are available from the corresponding author upon request). Compared to MRL/ lpr mouse sera, sera from STAT-1 2/2 mice had significantly increased levels of TNFa, IL-4, and eotaxin 1, in addition to significantly decreased levels of IL-12p40, a cytokine that is critical for Th1 polarization (38) . IRF-9 2/2 mouse sera also had significantly increased levels of IL-4 and IL-1a compared to MRL/lpr mouse sera. Based on these findings, IL-4 and IL-12 were added to our stimulation panel.
Phospho-flow profiling resulted in 1,980 data nodes, where each node represents phosphorylation lev- , or IRF-9 2/2 mice. The Significance Analysis of Microarrays (SAM) algorithm was used to determine antigen features with statistically significant differences in reactivity between sera from MRL/lpr, STAT-1
, and IFNAR-2 2/2 mice. a and b, Hierarchical clustering of samples based on antigen reactivity with statistically significant differences, displayed as a heatmap and dendrogram. Sera from STAT-1 2/2 and MRL/lpr mice were used to probe autoantigen arrays and detected with anti-IgM (a) and anti-IgG (b) secondary antibodies. Sera from IRF-9 2/2 and MRL/lpr mice were subjected to the same methods (data available from the corresponding author upon request). and MRL/lpr mouse B cells stimulated alone or with interferon-a (IFNa) for 4 hours. P values were determined by Mann-Whitney test. U1 sRNP68 5 U1 small nuclear RNP 68; dsDNA 5 double-stranded DNA. els of an individual STAT protein, in response to a single stimulation in a unique cell subset. STAT-1 2/2 mice showed no STAT-1 phosphorylation across all cell subsets (Figure 5a ). In response to IFNa, STAT-3 phosphorylation was significantly increased in all subsets of STAT-1 2/2 mice compared to MRL/lpr mice (results are available from the corresponding author upon request). IFNa stimulation also resulted in significantly increased STAT-4 phosphorylation, in both CD41 and CD81 T cells from STAT-1 2/2 mice compared to MRL/lpr mice. These data strongly suggest that IFNa can signal through STAT-3/4. IRF-9 2/2 mice had increased STAT-3 phosphorylation in CD81 T cells as well as in CD191 B cells after IFNa stimulation. Significantly increased STAT-4 phosphorylation was observed in CD41 and CD81 T cells from IRF-9 2/2 mice in response to IFNg stimulation compared to MRL/lpr T cells (results are available from the corresponding author upon request). All cell subsets in IFNAR-2 2/2 mice exhibited significantly reduced phosphorylation of STATs 1, 3, 4, and 5 in response to IFNa stimulation compared to MRL/lpr mice (results are available from the corresponding author upon request). Interestingly, enhanced phosphorylation of STAT-5 in response to IL-27 was significantly observed in both CD41 and CD81 T cells from IFNAR-2 2/2 mice compared to MRL/lpr mice. This result shows that in the absence of IFNAR-2, IL-27 signaling can be modulated from phosphorylation of STAT-1/3 to phosphorylation of STAT-5. It serves as additional evidence of STAT redundancy in different biologic states.
DISCUSSION
Using highly multiplexed analyses, we showed how loss of the individual type I and type II IFN signaling molecules IFNAR-2, IRF-9, and STAT-1 affects renal disease, autoantibody profiles, T cell subsets, and cytokine signal transduction. Notably, genetic deletion of STAT-1 leads to decreased autoantibody production and GN, but induces severe interstitial inflammation accompanied by infiltration of RORgt1 cells, CD451 leukocytes, macrophages, and eosinophils in the interstitium. STAT-1 ablation results in altered signal transduction characterized by shunting to STAT molecules, including STAT-3, a key transcription factor involved in Th17 cell differentiation. Our findings demonstrate a critical role for STAT-1 in the development of Th17-associated autoimmune interstitial kidney disease in a murine model of SLE.
Prevention and treatment of kidney disease is a crucial aspect of the management of SLE. Despite a reported prevalence of tubulointerstitial nephritis in SLE kidney biopsy specimens ranging from 23% to 72% (18, 39) , little is known regarding the immunologic mechanisms underlying tubulointerstitial nephritis. Most histologic measures focus on glomerular involvement to inform therapeutic decisions, but have suboptimal predictive value in renal outcomes. In contrast, multiple groups have shown that SLE patients with tubulointerstitial nephritis are at greatest risk of renal failure, requiring long-term dialysis or renal transplantation (18, 40 , or MRL/lpr mice with predominant GN, showed elevation in the kidney markers BUN and creatinine. These results suggest that tubulointerstitial nephritis, more so than GN, contributes to decreased renal function in MRL/lpr mice.
IL-17A is thought to play an important role in SLE pathogenesis (41) . The proportion of Th17 cells in the blood of SLE patients is elevated and correlates with the SLEDAI and with the presence of lupus nephritis (23) . IL-17 levels are also elevated in SLE sera (42) . Kidney-specific expression of IL-17A-producing cells is more controversial (43, 44) . We instead focused on the transcription factor RORgt. We demonstrated RORgt staining in the renal interstitium with concurrent staining of IBA-1 in STAT-1 2/2 mice but not in MRL/lpr mice. Costaining of eosinophils with RORgt1 cells in the interstitium of STAT-1 2/2 mice as compared to MRL/lpr mice further supports Th17 lymphocyte activity, since IL-17A up-regulates various cytokines that promote eosinophilic inflammation (25) . Multiplexed cytokine profiling studies also revealed increased levels of serum eotaxin 1, an eosinophil chemotactic chemokine, in STAT-1 2/2 mice compared to MRL/lpr mice. FACS analysis demonstrated significantly higher proportions of Th17 cells in lymph nodes and splenocytes derived from STAT-1 2/2 mice compared to MRL/ lpr mice. These data robustly support a role for STAT-1 in inhibiting Th17 lymphocyte polarization and trafficking to kidney interstitium in MRL/lpr mice.
Despite our findings, our study is limited by the inability to dissect independent effects of STAT-1 ablation on immune and renal parenchyma cells. Previous work has described elevated levels of IFNg mRNA in MRL/lpr mouse renal cells themselves (45) , resulting in the increased production of inflammatory cytokines, which induce apoptosis of cells involved in interstitial homeostasis (46) . Our finding of severe Th17-associated tubulointerstitial disease is unexpected in the setting of STAT-1 ablation, since IFNg signaling requires STAT-1 translocation to the nucleus. Adoptive transfer of STAT-1 2/2 mouse hematopoietic stem cells or IL-17-producing cells into MRL/lpr mice was unsuccessful due to difficulty with breeding and radiosensitivity of the MRL/lpr background strain. Further experiments are planned to shed light on the independent role of STAT-1 in renal versus hematopoietic cells.
Analysis of cytokine production and STAT phosphorylation in STAT-1 2/2 mouse splenocytes allowed us to investigate signaling mechanisms that could help explain differences observed in T helper cell polarization. We hypothesized that Th17 cell enrichment was associated with compensatory STAT-3/4 phosphorylation, both previously described in Th17 cell polarization (47) Phospho-flow data show no IFNa signaling in IFNAR-2 2/2 mice; however, these mice still have prominent autoantibody production and have marginally increased kidney pathology. Both of these indices have been associated with high IFN signaling rather than absence of IFN signaling (7, 8) . One potential explanation for the discrepancy between phenotypes of IFNAR-2 2/2 and STAT-1 2/2 mice is that MRL/lpr pathology is driven by IFNg, which requires STAT-1 for signal transduction through its receptor, and that IFNa is less influential. However, evidence shows that both IFNa and IFNg induce the formation of the ISGF-3 complex and bind to ISRE and g-activated site, respectively (48) . IFNa-and IFNg-inducible genes have 1242 YIU ET AL ;25% overlap, and the genes most highly up-regulated by IFNa are also IFNg inducible (49) . Notably, it remains unclear how IFN binding to receptors may be altered in the absence of a receptor subunit like IFNAR-2 (50). Treatment of MRL/lpr mice with a monoclonal anti-IFNAR antibody ameliorates disease at early time points. At later stages of disease, type I IFN signalingindependent pathways overcome the therapeutic effects (51). Mangini et al (52) posit that one of these pathways is downstream of IFNg, suggesting interactions between type I and type II IFN signaling pathways. We demonstrate direct evidence of cross-talk with increased IFNg production in the secondary lymphoid organs of IFNAR-2 2/2 and IRF-9 2/2 mice. Cross-talk can likely be attributed to shared phosphorylation of STAT-1 downstream of IFNa and IFNg and promiscuity of STAT phosphorylation.
Our studies highlight the complexity of type I and type II IFN signaling and the necessity for mechanistic studies in implementing therapies targeting IFNs and JAK/STATs. Our STAT-1 2/2 mouse model of Th17-associated tubulointerstitial nephritis may lead to a better understanding of JAK/STAT inhibitors like tofacitinib, which inhibits JAK-1/3. While there are no reports of tofacitinib-induced tubulointerstitial nephritis, no murine studies have addressed the effects of JAK-1/3 inhibition on autoimmune nephropathy. The IFN-targeted therapies sifalimumab (MEDI-545) and rontalizumab (RG7415) are still in early-stage clinical trials, and may be beneficial in specific subsets of patients (2) . Taken together, the findings of the present study reveal unique contributions of IFN signaling proteins to SLE pathogenesis and highlight a role for STAT-1 in interstitial kidney disease in MRL/lpr mice. These results improve our understanding of clinically important tubulointerstitial nephritis and will guide studies of targeted therapies in patients.
